Masimo Announces FDA Clearance and Full Market Release of the New Pronto-7 for Noninvasive Total Hemoglobin Spot-Check Measurement
Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance and full market commercial launch of the Masimo Pronto-7®—a palm-sized handheld device designed for quick and easy noninvasive spot-checking of total hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.